Literature DB >> 24688105

Immune suppression for childhood acquired aplastic anemia and myelodysplastic syndrome: where next?

Sujith Samarasinghe1, Judith Marsh, Carlo Dufour.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24688105      PMCID： PMC3971066          DOI： 10.3324/haematol.2014.105569

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  19 in total

1.  Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation (EBMT).

Authors:  Anna Locasciulli; Rosi Oneto; Andrea Bacigalupo; Gerard Socié; Elisabeth Korthof; Albert Bekassy; Hubert Schrezenmeier; Jakob Passweg; MoniKa Führer
Journal:  Haematologica       Date:  2007-01       Impact factor: 9.941

2.  Treatment of severe aplastic anemia with a combination of horse antithymocyte globulin and cyclosporine, with or without sirolimus: a prospective randomized study.

Authors:  Phillip Scheinberg; Colin O Wu; Olga Nunez; Priscila Scheinberg; Carol Boss; Elaine M Sloand; Neal S Young
Journal:  Haematologica       Date:  2009-01-30       Impact factor: 9.941

3.  Immunosuppressive treatment for aplastic anemia: are we hitting the ceiling?

Authors:  Jakob R Passweg; André Tichelli
Journal:  Haematologica       Date:  2009-03       Impact factor: 9.941

4.  Horse versus rabbit antithymocyte globulin in acquired aplastic anemia.

Authors:  Phillip Scheinberg; Olga Nunez; Barbara Weinstein; Priscila Scheinberg; Angélique Biancotto; Colin O Wu; Neal S Young
Journal:  N Engl J Med       Date:  2011-08-04       Impact factor: 91.245

5.  Changes in cytokine profile pre- and post-immunosuppression in acquired aplastic anemia.

Authors:  Carlo Dufour; Elisa Ferretti; Francesca Bagnasco; Oriana Burlando; Marina Lanciotti; Ugo Ramenghi; Paola Saracco; Maria Teresa Van Lint; Daniela Longoni; Giovanni Fernando Torelli; Marta Pillon; Anna Locasciulli; Aldo Misuraca; Milena La Spina; Andrea Bacigalupo; Vito Pistoia; Anna Corcione; Johanna Svahn
Journal:  Haematologica       Date:  2009-07-07       Impact factor: 9.941

6.  Comparison between horse and rabbit antithymocyte globulin as first-line treatment for patients with severe aplastic anemia: a single-center retrospective study.

Authors:  Elias Hallack Atta; Danielle Saldanha Peixoto Dias; Vera Lúcia Neves Marra; Alexandre Mello de Azevedo
Journal:  Ann Hematol       Date:  2010-04-07       Impact factor: 3.673

7.  Long-term outcome after immunosuppressive therapy with horse or rabbit antithymocyte globulin and cyclosporine for severe aplastic anemia in children.

Authors:  Dae Chul Jeong; Nack Gyun Chung; Bin Cho; Yao Zou; Min Ruan; Yoshiyuki Takahashi; Hideki Muramatsu; Akira Ohara; Yoshiyuki Kosaka; Wenyu Yang; Hack Ki Kim; Xiaofan Zhu; Seiji Kojima
Journal:  Haematologica       Date:  2013-11-08       Impact factor: 9.941

8.  Long-term outcome of pediatric patients with severe aplastic anemia treated with antithymocyte globulin and cyclosporine.

Authors:  Phillip Scheinberg; Colin O Wu; Olga Nunez; Neal S Young
Journal:  J Pediatr       Date:  2008-07-30       Impact factor: 4.406

9.  Deficient CD4+ CD25+ FOXP3+ T regulatory cells in acquired aplastic anemia.

Authors:  Elena E Solomou; Katayoun Rezvani; Stephan Mielke; Daniela Malide; Keyvan Keyvanfar; Valeria Visconte; Sachiko Kajigaya; A John Barrett; Neal S Young
Journal:  Blood       Date:  2007-04-26       Impact factor: 22.113

10.  Comparison of horse and rabbit antithymocyte globulin in immunosuppressive therapy for refractory cytopenia of childhood.

Authors:  Ayami Yoshimi; Marry M van den Heuvel-Eibrink; Irith Baumann; Stephan Schwarz; Ingrid Simonitsch-Klupp; Pascale de Paepe; Vit Campr; Gitte Birk Kerndrup; Maureen O'Sullivan; Rita Devito; Roos Leguit; Miguel Hernandez; Michael Dworzak; Barbara de Moerloose; Jan Stary; Henrik Hasle; Owen P Smith; Marco Zecca; Albert Catala; Markus Schmugge; Franco Locatelli; Monika Führer; Alexandra Fischer; Anne Guderle; Peter Nöllke; Brigitte Strahm; Charlotte M Niemeyer
Journal:  Haematologica       Date:  2013-10-25       Impact factor: 9.941
View more
  5 in total

1.  Induction of short-term remission with single agent eltrombopag in refractory nucleophosmin-1-mutated acute myeloid leukemia.

Authors:  Uwe Platzbecker; Katja Sockel; Claudia Schönefeldt; Daniel Nowak; Susann Helas; Christoph Röllig; Maximilian Mossner; Johann Christoph Jann; Gerhard Ehninger; Wolf-Karsten Hofmann; Martin Bornhäuser; Christian Thiede; Martin Wermke
Journal:  Haematologica       Date:  2014-09-05       Impact factor: 9.941

Review 2.  Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015.

Authors:  A Sureda; P Bader; S Cesaro; P Dreger; R F Duarte; C Dufour; J H F Falkenburg; D Farge-Bancel; A Gennery; N Kröger; F Lanza; J C Marsh; A Nagler; C Peters; A Velardi; M Mohty; A Madrigal
Journal:  Bone Marrow Transplant       Date:  2015-03-23       Impact factor: 5.483

Review 3.  Myelodysplastic and myeloproliferative disorders of childhood.

Authors:  Henrik Hasle
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

4.  Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022.

Authors:  John A Snowden; Isabel Sánchez-Ortega; Selim Corbacioglu; Grzegorz W Basak; Christian Chabannon; Rafael de la Camara; Harry Dolstra; Rafael F Duarte; Bertram Glass; Raffaella Greco; Arjan C Lankester; Mohamad Mohty; Bénédicte Neven; Régis Peffault de Latour; Paolo Pedrazzoli; Zinaida Peric; Ibrahim Yakoub-Agha; Anna Sureda; Nicolaus Kröger
Journal:  Bone Marrow Transplant       Date:  2022-05-19       Impact factor: 5.174

Review 5.  Missing Cells: Pathophysiology, Diagnosis, and Management of (Pan)Cytopenia in Childhood.

Authors:  Miriam Erlacher; Brigitte Strahm
Journal:  Front Pediatr       Date:  2015-07-13       Impact factor: 3.418
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.